Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

Vadim Tieroshyn1*, Larisa Moroz2, Oleksandra Prishliak3, Lyudmila Shostakovich-Koretska4, Oksana Kruglova5 & Lyudmila Gordienko6

The acute diarrhea is a wide-spread disease. The prescription of enterosorbents is appropriate as a primary measure for the treatment of the acute diarrhea for effective prevention of the fluid and electrolyte loss, as well as method for symptom relief of the attack of the disease. Aim of the study - the antidiarrheal efficacy and safety study of high-dispersion silicon dioxide enterosorbent in tablet dosage form in patients with acute diarrhea. This was randomized, double-blind, placebo-controlled, 4-center study. Acute diarrhea was defined as three and more episodes of watery stool per day either during 48 hours or less before study entry in the patients having normal stool recently. It has been postulated that symptoms and signs of acute diarrhea have to be caused by direct infection of the gastrointestinal tract and did not associated with moderate-to-severe systemic states. 144 patients with established acute diarrhea were randomized into treatment group (enterosorbent “Carbowhite”, n = 120) or placebo group. Date collection including severity diarrhea, systemic symptoms was performed at baseline and daily during 7 days. Stool examination and serological assay were performed at baseline. The primary end points were declared as time to complete recovery from acute diarrhea. It has been found that the use of the siliceous enterosorbent (“Carbowhite”) allowed to reduce (p < 0.001) the treatment period averagely for 0.9 days (95% confidence interval 0.5–1.2 days) in comparison with placebo. Data of safety monitoring has revealed that both patient groups had negative stool culture, while initiation of antibiotic treatment was run more frequently in placebo group (8.3%) compared to investigational product group (4.1%, P = 0.044). The siliceous enterosorbent “Carbowhite” was well tolerated and reduced the recovery time of the acute episode of the diarrhea in the clinically significant form.

The acute infectious diarrhea is a challenge for the contemporary medicine, although the leading factors contributing in the pathogenesis of the disease is well known1. However, there is a large body of evidence regarding higher rate of morbidity and mortality in developing countries due to diarrheal diseases2,3. Moreover, the acute diarrheal diseases are also wide-spread in the countries with high sanitary-hygienic level1. Foodborne Disease Burden Epidemiology Reference Group finds that the global burden of diarrheal diseases is comparable to those of the major infectious diseases, as HIV/AIDS, malaria and tuberculosis4.

1Kharkiv National Medical University, Kharkiv, Ukraine. 2Vinnytsya National Medical University named after M. I. Pirogov, Vinnytsya, Ukraine. 3Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine. 4Dnipro State Medical Academy, Dnipro, Ukraine. 5Lugansk State Medical University, Rubizhne, Ukraine. 6Kiev City Clinical Hospital No.9, Kiev, Ukraine. *email: v.a.teryshin@gmail.com
The attacks of diarrhea are usually brief and self-limiting, but the symptoms cause discomfort and are incapacitating. It is well-known that these symptoms lead to the substantial social marginal costs, as it is supposed that the half of the occurred episodes results in working days lost. The acute diarrhea is also the most frequent health disorder in travellers. Traveller’s diarrhea leads to the substantial discomfort as a result of the interference in the travelling routes, changes of business opportunities and revenue from tourism. Prevention of traveler’s diarrhea should be ideally based on the dietary restrictions, but the clinical experience demonstrates that this aim is extremely difficult to achieve.

Symptomatic therapy is still the important aspect of acute diarrhea treatment. There are several options of acute diarrhea treatment, including oral rehydration, anticholinergic, antisecretory and antibacterial medicinal products, probiotics and intestinal adsorbents. Intestinal adsorbents are a group of specific products, which adsorb and excrete present in the intestine gases, pathogens, allergens, exotoxins and endotoxins from the body. Based on safety and efficacy data of enterosorbents administration, it has been concluded that administration of these products can be recommended as a primary tool for the acute diarrhea treatment for rapid and effective prevention of fluid and electrolyte loss and symptom improvement.

The aim of the study was to investigate the antidiarrheal efficacy and safety of the siliceous enterosorbent (“Carbowhite”) in original tablet form in patients with acute diarrhea.

**Methods**

The initial hypothesis that is tested in the study is whether the treatment with original enterosorbent “Carbowhite” is better than placebo to reduce recovery period in patients with acute diarrhea.

**Study design.** It was a randomized, double-blind, placebo-controlled, 4 centres’ study. The study was registered in ClinicalTrials.gov (Identifier: NCT03633344, first posted 16/08/2018, result first posted 06/06/2019).

**Sample size calculation.** The sample size calculation was made using G*Power 3.1.5 (Heinrich-Heine-Universität Düsseldorf, 1992–2013) (alpha error = 0.05, beta error = 0.80). Total number of selected participants was calculated as 165 patients including drop-out percent (1%). A final number of randomised individuals was 144 (120 for active treatment and 24 for placebo in ratio 5-to-1) to achieve estimated treatment effect for the placebo and silicon dioxide group equal 1 day and more. An anticipated percent expected treatment effects for the placebo and treatment groups were defined as completed recovery time of acute diarrhea and this period has been expected for 2 days and 1 day after treatment run-in, respectively. Based on this assumption we have finally calculated sample size to identify the difference in primary effect between placebo and investigating product equal 1 day and more. The confidence level is defined as 95%, confidence interval was indicated as 1 day, and estimated sample size was 124 patients.

**Patients’ population.** Figure 1 is presented a flow chart with screening, randomization, treatment and monitoring procedures across the study. The patients were recruited from an inpatient hospital ward, office visit, and emergency room. Patients’ inclusion criteria were male and female subjects, age from 18 to 55 years old; acute diarrhea (more than 3 episodes of watery stool a day) during 48 hours or less in patients with normal stool usually; body temperature ≤ 38 °C; patient’s ability to adequately cooperate during the study, and written informed consent. Patients’ exclusion criteria were age < 18 or > 55 years old; the blood or pus in stool; the body temperature > 38 °C; the episodes of acute diarrhea for the last 30 days; food intolerance-related diarrhea; medication related diarrhea including antibiotic-associated diarrhea, functional diarrhea; systemic bacterial infections; travel-associated systemic infections including malaria, dengue fever and SARS; HIV infection associated diarrhea; Clostridium difficile infection; other extra intestinal infections; the administration of anti-diarrheal
medicinal products during 24 hours; salmonellosis (Salmonella of any serotype, different from S. typhi and S. paratyphi; ICD-10 code: A02.0), dysentery (Shigella dysenteriae, Shigella flexneri, Shigella boydii; ICD-10 code: A03.0-A03.3), escherichiosis (Escherichia coli; ICD-10 code: A04.0-A04.4) requiring prescription of antibacterial drugs; pregnancy, lactation; concomitant decompensated diseases or acute conditions, in investigator’s opinion, are able to effect on the study results; alcoholism and drug abuse; participation in any other clinical studies.

**Acute diarrhea determination.** Conventionally, acute diarrhea without relation reason (infection or non-infection) is defined as an abnormally frequent discharge of semisolid or fluid fecal matter from the bowel, lasting less than 14 days. Acute infectious diarrhea was defined as three and more episodes of watery stool per day during 48 hours or less before study entry in patients with initially normal stool19. It has been postulated that symptoms and signs of acute diarrhea have to be caused by direct infection of the gastrointestinal tract and did not associated with moderate-to-severe systemic states20. Any extra intestinal reasons leading to acute diarrhea, as well as non-infectious causes related to inflammatory bowel disease, were not considered ethological factors for acute diarrhea20,21. Patients with other non-infectious diarrhea that affected extra intestinal organ systems, such as food intolerance, medication related diarrhea, functional diarrhea, were not enrolled as candidates for the study participants.

**Randomization procedure.** Previously 1:1 randomization was planned to minimize restricted other randomizations, which can be associated with small groups, and prevent from statistical bias due to incorrect validation of disease severity in different study centres22,23. However, Steering Committee of Health Ministry of Ukraine has proposed to randomly allocate all enrolled patients in 5:1 ration (treatment versus placebo group) to minimize a placebo effect. According to the inclusion/exclusion criteria 144 patients from four centres were enrolled in this study. Patients were randomized into treatment and placebo groups with IWRS (Interactive Web Response System) system22. Participants were randomly assigned following simple randomization procedures (computerized random numbers) to investigational product (IP) group or placebo24. Finally, the 1st group (120 patients) administered the IP siliceous enterosorbent (“Carbowhite”), the 2nd group (24 patients) administered placebo.

**Treatment regimen.** Every tablet of “Carbowhite” contains 210 mg of high-dispersion silicon dioxide with the area of active sorption surface no less than 300 square meters per one gram of a substance, and was produced by the licenced producer Pharmex Group LLC (Ukraine). Every tablet of placebo was produced identically to the investigational enterosorbent without active ingredients (with powder of chalk) by the same producer.

The siliceous enterosorbent (“Carbowhite”) or placebo was prescribed to the patients with acute diarrhea in the following dosage regimen: the investigational enterosorbent/placebo were prescribed in the dose: 3 tablets per one administration (210 mg × 3 = 630 mg) four times a day (630 mg × 4 = 2520 mg). At insufficient anti-diarrheal efficacy (no reduction of stool frequency (for a day) from the moment of beginning of a patient’s treatment), it was possible to increase the dose in two steps: step 1 – 4 tablets per one administration (210 mg × 4 = 840 mg) four times a day (840 mg × 4 = 3360 mg) during 1–2 days, and step 2–5 tablets per one administration (210 mg × 5 = 1050 mg) four times a day (1050 mg × 4 = 4200 mg) for Day 2, Day 3, Day 4 of treatment. Study duration for each patient was 7 days.

**End point determination.** The primary endpoint was run as a time to complete recovery from acute diarrhea.

**Data collection.** Research collaborators collected data daily, completed a standardized, and refined electronic case report form25. Complaints, clinical status, anamnesis, medical and family history, concomitant medication, adverse events, and new medications were collected at screening, at baseline and at every visit of the patients in the hospital. It has been planned a call of patients to investigator if needed. All patients were previously screened systemic infections, including HIV, hepatitis, tuberculosis, as well as inflammatory bowel disease and autoimmune disease. Clostridium difficile Infection was excluded using contemporary procedure26. Cultural and serological investigations were performed according to contemporary protocol to rule-out salmonellosis, dysentery, and escherichiosis as it was described above27.

All contacts were specified in source documents and verified by principal investigator. Stool frequency was reported by the patient using personal original diary, with was reviewed by investigator before observation at the visit. The diary was validated for this study and approved by Institutional Review Board before study entry. Stool consistency was assay using validated Bliss Stool Classification System28, which has been completed at the visit and then reported. All completed charts were collected and stored as source document. All collected data were reported on-line through completing electronic case report forms. Additionally we reported all endpoints as soon as they had appeared and reported them to the monitor(s) and collected data around these events. Reporting of the events included identification of adverse events or not, specification of incidence, severity and timing or duration of them.

**Blinding procedure.** The study was constructed to be blinded participants being enrolled, included and treated, clinical staff administering, and the team interpreting results. However, data collectors were independent and they were unaware of the treatment the participant received29. In fact, all participants and study staff were blinded and the study was defined as double blind study.

**Unblinding procedure.** The unblinding process was embedded onto study protocol and the participant and/or study team of which treatment the participant received during the study had a possibility to disclose the investigatig product (active drug or placebo) using IWRS30. To protect participants in the event of medical or safety reasons unblinding procedure could be made due to request of central advisor committee, IRB, staff person, or
authority if needed. After unblinding procedure patient was excluded from the study and it did not run to participate in the study again.

Efficacy monitoring. The primary efficacy parameter was a percentage of patients administered the investigational product (IP) who has gained the efficacy endpoint (the reduction of defecation to 3 times a day, no liquid stool). The secondary efficacy parameter was a percent of patients administered the IP who has discontinued the study, the average treatment duration and average quantity of tablets for treatment course. The end treatment criteria were reduction of stool frequency to 3 and less times a day, bacteriological diagnosis verification with the consequent antibacterial therapy beginning, development of adverse reactions associated, in the opinion of the physician-investigator, with the administration of the IP/placebo. During the study the concomitant therapy with other sorbents, probiotics, prokinetics and antimicrobial medicines was prohibited.

Safety monitoring. The primary safety parameter was a percentage of patients administered the IP who had undesirable effects (adverse reactions/adverse effects – AR/AE). The secondary safety parameter was dynamics of vital sign change, dynamics of body weight change, and laboratory test values. Data regarding a number of patients received positive and negative stool culture, as well as frequency of antibiotics initiating were reported.

Anthropometry. Anthropometric measurements including body weight and height were made at the baseline using standard procedures.

Declaration on ethical principles. This study was performed in accordance with the Law of Ukraine “On medicines” (No. 124/96-BP, in the wording of 19.06.2016), the Declaration of Helsinki and the Procedure for Conducting Clinical Trials of Medicinal Products and Expert Evaluation of Materials Pertinent to Clinical Trials and Model Regulations on the Ethics Committee. The study has been performed upon authorization and under control of the State Expert Centre of the Ministry of Health of Ukraine and finished on Oct 7, 2016 (National Identification number was CRICOD-7-180).

Local Ethical Committees of Vinnytsya City clinical hospital No. 1, Ivanо-Frankivsk regional infectious diseases clinical hospital, Kyiv City clinical hospital No. 9, Dnipro City clinical hospital No. 21 approved the study protocol in Feb 10, 2016, Feb 22, 2016, Feb 10, 2016 and Feb 18, 2016 respectively.

All individuals included in the study have given written informed consent. The informed consent forms (ICFs) were approved by an appropriate regulatory chair of the State Expert Center of the Ministry of Health (Ukraine) and were updated as needed.

Statistics. We used MedCalc v.16.8.4 (MedCalc Software Inc., Broekstraat, Belgium), G*Power 3.1.5 (Universität Kiel, Germany) for statistics. Quantitative variables were expressed as mean (M) and standard deviation (±SD), median and interquartile range (IQR), estimated marginal mean (95% confidence interval [CI]) or number (percentage). An independent group t-test was used to compare all the interval parameters matching the criteria of normality and homogeneity of variance. For interval parameters that fail to match these criteria, the non-parametric Mann-Whitney test was used to compare variables. The Fisher’s Exact Test and Chi-square Test were used at comparison of efficacy of treatment vs. placebo effect. During analysis of the dynamics of parameter changes, ANOVA methods for the repeated measurements (or their non-parametric analogue) were used. The logistic regression models were used for the potential risk factors for treatment failure. The ROC (receive operation curve characteristics) analysis was used to evaluate the logistic regression model. The power of the model’s predicted values to discriminate between positive and negative cases is quantified by the Area under the ROC curve (AUC). Odds ratio (OR) index and its 95% CI were calculated for assessment of the extent of the factors effect within the frameworks of the logistic regression model. The risk ratio (RR) indexes and the average number of patients who need to be treated (Number-Needed-to-Treat NNT) and their 95% CI were used for assessment of the IP efficacy in comparison with placebo. Odds ratio (OR) index and its 95% CI were calculated for assessment of the extent of the factors effect within the frameworks of the logistic regression model. P value between groups has been chosen equal to 0.05.

Results
The study population has consisted of 144 subjects (85 males and 59 females) with mean age 31.5 years (from 18 years to 58 years). The baseline data of eligible individuals are listed in Table 1. The statistically significant difference in distribution by gender between subgroups has not been detected (p > 0.05). Consequently, there was no statistically significant difference in parameter value in both subgroups at the baseline (p > 0.05).

24 patients administering placebo and 120 patients administering the IP (“Carbowhite”) have been treated during the first 24 hours. The dynamics of the analysed parameters is represented in Table 2. The analysis of treatment efficacy among the patients administered with IP/placebo have yielded that sufficient clinical improvement (i.e., 3 defecation acts, no watery stool) has achieved in 59 patients in the IP group and in 1 patient only in the placebo group at the end of the first treatment day.

The parameter values after 2nd, 3rd, 4th days of treatment are represented in Table 3. After two days of the treatment, the effect has achieved in other 36 patients in the IP group, the total number of patients who have successfully finished the active treatment period with the IP was 95 individuals. Eleven patients in the placebo group have finished treatment.

In three days of treatment (Table 3), clinical efficacy has been observed in other 23 patients in the IP group (total number of successfully treated patients is 118) and among 8 patients in the placebo group (total number of successfully treated patients is 20).
The analysis of treatment failure risk. Patient treatment results of 2 groups are represented in Table 4. Analysis has revealed that on the 1st, 2nd and 3rd day the treatment failure risk in the IP group was lower (p < 0.05 for all cases) than in the placebo group (Fig. 4). Consequently, on the 2nd day of the treatment (control point) the treatment failure risk in the placebo group was 50% (95% CI 29.5–70.5%), and in the IP group it was 20.8% (95% CI 14.0–28.6%). It was associated with a 2.5-fold reduction of the risk (p = 0.01) in the IP group (RR = 0.4 (95% CI 0.3–0.7) (NNT = 3.4 (95% CI 2.0–11.2)).

The univariate and multivariate logistic regression analysis. The univariate logistic regression analysis has revealed significant reduction (p = 0.004) of treatment failure risk at the use of the IP (OR = 0.26 (95% CI 0.11–0.66) versus placebo (Table 5). The multivariate logistic regression model of the IP effect on the treatment failure risk was performed after adjustment to the patient’s age, sex, body weight index, severity index at baseline (quantity of stool acts), and temperature at baseline. The multivariate logistic regression model was adequate (χ² = 2.15 at one degree of freedom, p = 0.002). The increase in the treatment failure risk for increased severity index at baseline for each act was determined (OR = 1.24; 95% CI 1.04–1.47 p = 0.015).

The analysis of investigation product number. The performed analysis demonstrates that in the IP group the average number of tablets for 3 acts was 12 pcs. (Q₁ = 12 pcs. – Q₃ = 24 pcs.), minimum/maximum quantity of tablets was 12 pcs and 48 pcs, respectively. In the placebo group the average number of tablets for 3 acts was 30 pcs. (Q₁ = 24 pcs. – Q₃ = 36 pcs.), minimum/maximum quantity of tablets was 12 pcs and 48 pcs, respectively.

The analysis of end point for the study. The primary end points have been declared as time to complete recovery from acute diarrhea. The analysis has demonstrated that the mean value of the treatment duration to the...

### Table 1. The patient characteristics at the baseline. Abbreviations: Me – median; IQR – 27%-75% interquartile range; BP – blood pressure; SD – standard deviation; HR – heart rate; T – body temperature.

| Parameter                  | Placebo subgroup (n = 24) | Treatment subgroup (n = 120) | Entire group (n = 144) | P value |
|----------------------------|----------------------------|-----------------------------|------------------------|---------|
| Age, Me (IQR), years       | 34.8 (23.9–47.6)          | 30.9 (22.9–35.0)            | 31.5 (23.3–36.1)       | 0.20    |
| Male/female, n             | 12/12                     | 73/47                       | 78/66                  |         |
| Height, T ±SD, cm          | 173.1 ± 8.1               | 175.4 ± 8.6                 | 175.0 ± 8.5            | 0.23    |
| Weight, Me (IQR), kg       | 70.5 (65.0–84.5)          | 72.5 (66.5–80.5)            | 72.0 (65.5–81.0)       | 0.99    |
| SBP, Me (IQR), mm Hg       | 80 (70–80)                | 80 (70–80)                  | 80 (70–80)             | 0.84    |
| DBP, Me (IQR), mm Hg       | 120 (110–120)             | 120 (112.5–120)             | 120 (110–120)          | 0.50    |
| HR, Me (IQR), b/min        | 83.0 ± 5.4                | 81.7 ± 6.2                  | 81.9 ± 6.0             | 0.31    |
| T, °C ±SD, °C              | 37.55 ± 0.28              | 37.44 ± 0.51                | 37.46 ± 0.31           | 0.54    |
| Stool frequency, n         | 7.8 ± 2.1                 | 7.0 ± 2.4                   | 7.1 ± 2.3              | 0.12    |
| Dose, tablets              | 12                        | 12                          | 12                     | 1.0     |

### Table 2. The dynamics of parameter changes on the 1st day of treatment. Abbreviations: IQR – interquartile range; T – body temperature; Me – median; SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – heart rate; SD – standard deviation.

| Parameter                  | Placebo group (n = 24) | Treatment group (n = 120) | P value |
|----------------------------|------------------------|----------------------------|---------|
| Weight, Me (IQR), kg       | 70.5 (65.0–84.5)       | 73.0 (66.5–80.5)           | 0.98    |
| DBP, Me (IQR), mm Hg       | 77.5 (70–80)           | 80 (70–80)                 | 0.45    |
| SBP, Me (IQR), mm Hg       | 120 (117.5–120)        | 120 (117.5–120)*           | 0.24    |
| HR, T ±SD, b/min           | 74.9 ± 3.3*            | 74.7 ± 3.8*                | 0.79    |
| T, °C ±SD, °C              | 36.78 ± 0.30*          | 36.70 ± 0.22*              | 0.26    |
| Acts, ±SD, times           | 5.0 ± 1.9*             | 3.7 ± 2.3*                 | <0.001  |
| Dose, tablets ±SD, tablets | 13.2 ± 1.9             | 12.4 ± 1.2                 |         |

On the 4 day of the observation period (Table 3), the treatment with the IP/placebo has finished for the rest of 2 patients in the IP group, and 4 patients in the placebo group. All patients in both the IP and placebo groups have completely recovered at the end of four day. The dynamics of body temperature and acts in randomized patients are represented in Figs. 2 and 3.
The achievement of full clinical effect in the placebo group was 2.6 days (95% CI 2.3–3.0 days) and in the IP group it was 1.7 days (95% CI 1.6–1.9 days). Consequently, the use of the IP allowed significant (p < 0.001) reducing the treatment duration averagely for 0.9 days (95% CI 0.5–1.2 days) in comparison with placebo.

**Table 3.** The dynamics of parameter changes during the treatment. Abbreviations: IQR – interquartile range; T – body temperature; Me – median; SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – heart rate; SD – standard deviation.

| Parameter | Mean value 2nd day of treatment | Mean value 3rd day of treatment | Mean value 4th day of treatment | P value | Placebo group (n = 24) | Treatment group (n = 120) | Placebo group (n = 24) | Treatment group (n = 120) | P value |
|-----------|--------------------------------|--------------------------------|--------------------------------|---------|-----------------------|-----------------|-----------------------|-----------------|---------|
| Weight, Me (IQR), kg | 71.0 (65.5–84.8) | 73.0 (67.0–80.0) | 0.95 | 76.5 (67.5–86.5) | 73.0 (65.0–78.0) | 0.10 | 78.0 (63.5–99.0) | 71.5 (68.0–73.0) | 0.47 |
| DBP, Me (IQR), mm Hg | 75.0 (70–78) | 80 (70–80) | 0.86 | 77.5 (70–80) | 75 (70–80) | 0.86 | 75.5 (70–79) | 70 (70–75) | 0.32 |
| SBP, Me (IQR), mm Hg | 120 (120–120) | 120 (120–120) | 0.20 | 120 (120–120) | 120 (120–120) | 0.10 | 120 (120–120) | 120 (120–120) | 0.56 |
| HR, Me (IQR), b/min | 74.1 ± 2.7 | 73.9 ± 2.6 | 0.49 | 74.1 ± 2.8 | 73.1 ± 3.9 | 0.36 | 74.0 ± 2.5 | 74.0 ± 3.6 | 0.09 |
| T, °C ±SD | 36.64 ± 0.15 | 36.63 ± 0.21* | 0.43 | 36.62 ± 0.10 | 36.60 ± 0.15 | 0.39 | 36.57 ± 0.08 | 36.58 ± 0.10 | 0.63 |
| Acts, X ±SD, times | 3.5 ± 1.9* | 2.8 ± 1.4* | 0.10 | 2.8 ± 1.1* | 2.0 ± 0.9* | 0.03 | 2.1 ± 0.9* | 1.3 ± 0.5* | 0.09 |
| Dose, X ±SD, tablets | 13.3 ± 1.9 | 12.2 ± 1.0 | — | 13.7 ± 2.2 | 12.0 | — | 12.0 | — | — |

**Figure 2.** The dynamics of body temperature changes in patients. Note: Mean value and 95% CI are shown.

**Figure 3.** The dynamics of acts in patients. Note: Mean value and 95% CI are shown.
During analysis, the primary efficacy parameter was used as output variable $Y$. For patients for whom efficacy endpoint was achieved on the 2nd day and earlier, the value $Y = 0$ (107 patients), or alternatively $Y = 1$ (37 patients). Patient age, sex, and body weight, severity index at baseline (quantity of acts), temperature at baseline, and also the treatment procedure (IP/placebo) were used as the factors of further analysis.

Univariate logistic regression model was used to detect the effect of the IP to reduce recovery period in comparison with placebo. The obtained model was adequate ($\chi^2 = 8.0$ at one degree of freedom, $p = 0.005$). The received operating characteristic curve analysis has shown that AUC for placebo was 0.61 (95% CI 0.52–0.69) and for IP it was 0.76 (95% CI 0.68–0.83; $p < 0.05$). The best balanced cut-off point obtained by maximization of Youden test was 0.1754 (Fig. 4).

### Table 4. The dynamics of treatment efficacy changes. Abbreviations: M – mean; m – standard error of the mean; RR – risk ratio; CI – confidence interval; Abs. – absolute value.

| Effect | Abs. (M ± m%) | Placebo group (n = 24) | IP group (n = 120) | P value | RR (95% CI) |
|--------|---------------|------------------------|-------------------|---------|-------------|
| 1st day|               |                        |                   |         |             |
| Not achieved | 23 (95.8 ± 4.1) | 61 (50.8 ± 4.6) | <0.001 | 0.5 (0.4–0.6) |
| Achieved | 1 (4.2 ± 4.1) | 59 (49.2 ± 4.6) |         |         |             |
| 2nd day|               |                        |                   |         |             |
| Not achieved | 12 (50.0 ± 10.2) | 25 (20.8 ± 3.7) | 0.01 | 0.4 (0.3–0.7) |
| Achieved | 12 (50.0 ± 10.2) | 95 (79.2 ± 3.7) |         |         |             |
| 3rd day|               |                        |                   |         |             |
| Not achieved | 4 (16.7 ± 7.6) | 2 (1.7 ± 1.1) | 0.03 | 0.10 (0.02–0.52) |
| Achieved | 20 (83.3 ± 7.6) | 118 (98.3 ± 1.1) |         |         |             |
| 4th day|               |                        |                   |         |             |
| Not achieved | — | — | — | — | — |
| Achieved | 24 (100) | 120 (100) |         |         |             |

### Table 5. The parameter values of univariate and multivariate logistic regression model of forecasting the treatment failure risk. Abbreviations: b – beta coefficient; OR – odds ratio; CI – confidence interval; T – body temperature; SD – standard deviation.

#### Univariate logistic regression model

| Factor | Model parameter value, b ± SD | P value | OR (95% CI) |
|--------|-------------------------------|---------|-------------|
| Constant | 0.00 ± 0.41 | — | — |
| Treatment, investigational enterosorbent vs placebo | −1.36 ± 0.47 | 0.004 | 0.26 (0.11–0.66) |

#### Multivariate logistic regression model

| Factor | Model parameter value, b ± SD | P value | OR (95% CI) |
|--------|-------------------------------|---------|-------------|
| Constant | 0.00 ± 0.41 | — | — |
| Treatment, investigational enterosorbent vs placebo | −1.00 ± 0.50 | 0.047 | 0.37 (0.13–0.98) |
| Frequency of stool | 0.21 ± 0.09 | 0.015 | 1.24 (1.04–1.47) |
| Age | 0.031 ± 0.022 | 0.171 | — |
| Body Mass Index | 0.00 ± 0.07 | 0.998 | — |
| Male vs Female | −0.80 ± 0.45 | 0.075 | — |
| T | 0.75 ± 0.73 | 0.302 | — |

During analysis, the primary efficacy parameter was used as output variable $Y$. For patients for whom efficacy endpoint was achieved on the 2nd day and earlier, the value $Y = 0$ (107 patients), or alternatively $Y = 1$ (37 patients). Patient age, sex, and body weight, severity index at baseline (quantity of acts), temperature at baseline, and also the treatment procedure (IP/placebo) were used as the factors of further analysis.

Univariate logistic regression model was used to detect the effect of the IP to reduce recovery period in comparison with placebo. The obtained model was adequate ($\chi^2 = 8.0$ at one degree of freedom, $p = 0.005$). The received operating characteristic curve analysis has shown that AUC for placebo was 0.61 (95% CI 0.52–0.69) and for IP it was 0.76 (95% CI 0.68–0.83; $p < 0.05$). The best balanced cut-off point obtained by maximization of Youden test was 0.1754 (Fig. 5). The treatment failure risk adjusted by age, sex, body weight index, severity
index (quantity of acts) and temperature in the IP group was lowered (OR = 0.37 (95% CI 0.13–0.99; p = 0.046) in comparison with placebo.

Safety monitoring. Data of safety monitoring has revealed that both patient groups had negative stool culture, while initiation of antibiotic treatment was run more frequently in placebo group (8.3%) compared to IP group (4.1%, P = 0.044) (Table 6).

Thus, IP treatment was associated well with positive response from clinical status, reducing recovery period and good safety of the therapy.

Discussion

The data of the study have revealed that estimated efficacy of the tablet dosage form of the investigational enterosorbent (“Carbowhite”) in patients with acute diarrhea was superior placebo. The results of the study have yielded that IP treatment was significantly better when compared with placebo among patients with acute diarrhea having negative stool culture. Yet, a risk of treatment failure was found to be minimized in the IP group when compared with placebo.

Previous clinical observations have revealed that the most of the patients with acute diarrhea had a self-limiting disease course33,34, the main challenge for the physician is to discriminate patients for whom symptomatic therapy is sufficient from those with severe disease course and threatening complications5,35. There are several clinical guidelines with well-shaped methodology for prevention and treatment of acute diarrhea taken into consideration several factors that contribute in a prolongation of diarrhea persistence34–36. For instance, the antimotility drug loperamide and the secretion inhibitor racecadotril are considered as the first choice for the treatment of acute uncomplicated traveler’s diarrhea including traveler’s diarrhea and non-infection diarrhea35.

To note, a large number of patients with acute diarrhea who generally demand antibiotic therapy should be disabused of their expectations, and antibiotics should use only in complicated cases. Several clinical conditions, in which bacterial agents were not confirmed in stool specimens and a risk of Clostridium difficile infection is low, were associated with hypovolemia, hemodynamic disorders and electrolyte imbalance due to the prolongation of diarrhea37. Moreover, antibiotic use is agents with high potency to prolong diarrhea due to deteriorative effect.
on the microbiota. In this context, other therapeutic approaches including enterosorbents' use are currently available for the treatment of acute diarrhea. Indeed, previous clinical studies and meta-analysis have shown that tannin albumin in combination with ethacridine lactate have provided 36% protection from acute diarrhea, but both drugs were not widely available. Among the non-antimicrobial agents that were available and useful for the treatment of the patients with acute diarrhea was a bismuth subsalicylate-containing preparation, which has demonstrated decrease in the passage of loose stools by 16%-18%. The anti-secretory and anti-motility agent loperamide reduced the passage of loose stools by approximately 50% and has been especially useful, in combination with antimicrobial agents, in reducing the total duration of post-treatment diarrhea to a matter of hours.

Undoubtedly, greater attention should be paid to the monitoring and supervision of antibiotics as well as safety and tolerability of the any drugs that have been implemented into diarrhea treatment scheme. In fact, stool culture negative patients with acute diarrhea did not get benefit from acute or chronic antibiotic treatment, such as decrease in a need in hospital admission and hospital stay. In this context, enterosorbent like “Carbowhite” may have promising clinical efficacy regarding surge of completed recovery in diarrhea.

Although mild-to-moderate acute diarrhea in patients with negative stool examination might have spontaneously recovered, IP insured diminish of diarrhea symptoms. However, there are several difficulties to conduct a study of a disease where most patients seek no care and many spontaneously resolve quickly. Having a risk of pseudomembranous colitis and microbiota disorders after antibiotic use, enterosorbents may be promising drugs to recover diarrhea, because they have excellent profile of safety and tolerability. Interestingly, placebo group gained > 7 kg from the first day to fourth day that was probably associated with fluid retention after diarrhea recovery, while the implementation of the enterosorbent “Carbowhite” did not relate to this effect. There is evidence regarding oral intestinal enterosorbent Enterosgel (Polymethylsiloxane polyhydrate) that was orally administered materials which pass through the gut where they bind various substances. Despite it is recommended as a symptomatic treatment for acute diarrhea and it also demonstrated interactions with bile acids and numerous pharmaceutical drug including antibiotics, there is not face-to-face comparison between Enterosgel and Carbowhite, as well as between Enterosgel and placebo. Additionally, adsorption capacity for Enterosgel has varied, whereas this parameter for “Carbowhite” was dramatically lower.

However, large clinical trials are required to be provided to clearly explain the therapeutic profile of the enterosorbent “Carbowhite” in patients from several populations and various clinical conditions associated with acute diarrhea. Thus, based on interval estimation, the probability of the undesirable effects associated with the use of investigational enterosorbent is less than 1.6% (p = 0.05). Similar studies to study the efficacy of the enterosorbent “Carbowhite” had not previously been conducted.

Other clinical studies dedicated several methods of treatment of acute diarrhea have revealed numerous controversies. For instance, antibiotics have resolved acute diarrhea within 7 days (median was 3 days) after initiation of treatment versus 17 days in the placebo group. However, this effect was closely associated with broad spectrum of enteric protozoan pathogens and bacterial infections. Our study has shown that the difference between placebo and IP in diarrhea recovery period was 0.9 day, but the patients enrolled in the study did not exhibit positive stool culture. Therefore, acute diarrhea related to travel requires to be treated with antibiotics regardless of severity of disease to complete recovery.

The enterosorbent “Carbowhite” has been developed in Ukraine. It has a complex composition based on the features of high-dispersion colloidal silicon dioxide (SiO₂). Silicon dioxide blocks the receptors of mucous membrane responsible for pathogens adhesion and toxins binding, thus, accelerating the adsorption of active substances in the intestine. Moreover, silicon dioxide that is embedded in the structure of “Carbowhite” does not represent direct damage impact on intestinal wall and it does not provoke electrolyte disturbances. Importantly, there is no evidence regarding of accumulation of silicon dioxide in organs and tissues of animals was observed at its intake. The drug does not contain sugar; it can be used in patients with diabetes. Additionally, silicon dioxide promotes the movement from the internal environment of the body into the digestive tract of various toxic products, including medium molecules, oligopeptides, amines and other substances, due to concentration and osmotic gradients, followed by binding and excretion from the body. Therefore, there is a large body of evidence that silicon dioxide-based enterosorbents might have pleiotropic effects beyond adsorption of the intestinal products. It has been suggested that silicon dioxide may block the adhesive factors and cause denaturation of the adhesive proteins on the bacterial cell surface, disturbing the functional activity and adverse properties of the pathogenic microorganisms. Antimicrobial activity of silicon dioxide against enteric pathogens defines its anti-diarrheal effect; three-dimensional structure of the sorbent increases viscosity of the liquid media, causing anti-diarrheal and coating effect.

Thus, the randomized, double-blind, placebo-controlled, multi-center study efficacy of the administration of colloidal silicon dioxide in tablet form (“Carbowhite”) in patients with acute diarrhea was revealed that the high-dispersion silicon dioxide enterosorbent (“Carbowhite”) exhibited much more anti-diarrheal effect when compared with placebo. The treatment with the enterosorbent “Carbowhite” versus placebo is well tolerated by patients and does not cause adverse effects. These findings support the role of “Carbowhite” in acute diarrhoea especially in vulnerable groups where rapid resolution of symptoms is required.

Study limitations. The study design was limited by a small number of patients who were taking the investigational enterosorbent. The second limitation affects the method of randomization. Taking into consideration these previously reported findings we have decided that the 1:1 allocation during randomization was used in the study to prevent traditional bias regarding uncertain outcomes in patients with mild-to-moderate acute diarrhea that might recover spontaneously. We have allocated all patients’ number via ICRS through four centers in Ukraine, but Steering Committee of Health Ministry of Ukraine has not approved this randomization ratio and proposed changing from 1:1 to 5:1 aimed minimize a placebo effect in patients. We agree that this is a bias,
but this limitation should be taken into consideration further. The next study limitation is various etiologies of diarrhea, while infections as primary cause of the diarrhea were rule out in the study. Investigations of the quality of life among patients with diarrhea treated with - the enterosorbent “Carbowhite” are recommended to carry out in the future.

Received: 29 October 2018; Accepted: 10 March 2020;
Published online: 14 April 2020

References
1. Cottrell, J., Koenig, K., Perfekt, R. & Hofmann, R. Comparison of two forms of loperamide-simeticone and a probiotic yeast (Saccharomyces boulardii) in the treatment of acute diarrhea in adults: a randomised non-inferiority clinical trial. Drugs. 15(4), 363–373 (2015).
2. Lamberti, L. M., Walker, C. L. F. & Black, R. E. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. BMC public health. 12(1), 276 (2012).
3. WHO [World Health Organization]. WHO estimates of the global burden of foodborne diseases: foodborne disease burden epidemiology reference group 2007–2015, http://www.who.int/foodsafety/publications/foodborne_disease/fergreport/en/ (2015).
4. Kirk, M. D. et al. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS medicine. 12(12), e1001921 (2015).
5. Buzby, J. C. & Roberts, T. The economics of enteric infections: human foodborne disease costs. Gastroenterology. 136(6), 1851–1862 (2009).
6. Castelli, F., Saleri, N., Tomasoni, L. R. & Carosi, G. Prevention and treatment of traveler’s diarrhea. Focus on antimicrobial agents. Digestion. 73(1), 109–118 (2006).
7. Giddings, S. L., Stevens, A. M. & Leung, D. T. Traveler’s diarrhea. Med Clin North Am. 100(2), 317–330 (2016).
8. Laffont, M. A., Martin-Blondel, G. & Marchou, B. Management of traveler’s diarrhea. Rev Prat. 65(4), 505–508 (2015).
9. Lübbert, C. & Weis, S. Drug therapy of infectious diarrhea: part 1: acute diarrhea. Internist (Berl). 54(11), 1383–1392 (2013).
10. Gregorio, G. V., Gonzales, M. L. M., Dans, L. F. & Martinez, E. G. Polymer-based oral rehydration solution for treating acute watery diarrhea. Cochrane Database Syst Rev., https://doi.org/10.1002/14651858.CD006519.pub3 (2016).
11. Manatsathit, S. et al. Guideline for the management of acute diarrhea in adults. Journal of Gastroenterology and Hepatology. 17, 54–71 (2002).
12. Ruddle, M. S., DuPont, H. & Connor, B. A. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. Ann J Gastroenterol. 111(5), 602–622 (2016).
13. Stallmach, A., Hagel, S. & Lohse, A. W. Diagnostic workup and therapy of infectious diarrhea. Current standards. Internist (Berl). 56(12), 1353–1360 (2015).
14. Wingate, D. et al. Guidelines for adults on self-medication for the treatment of acute diarrhea. Alimentary Pharmacology & Therapeutics. 15, 773–782 (2001).
15. Zollner-Schwetlitz, J. & Brause, K. Therapy of acute gastroenteritis: role of antibiotics. Clin Microbiol Infect. 21(8), 744–749 (2015).
16. Dorn, M. Kontrollierte klinische Prüfung eines Antidiarrhoikums. Fortschritte der medizin. 146(2), 57–60 (2004).
17. Bergna, H. E. & Roberts, W. O. Colloidal Silica.: fundamentals and applications. Taylor Francis Group, CRC Press, 884 (2005).
18. Ogundimu, E. O., Altman, D. G. & Collins, G. S. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol. 76, 175–82 (2016).
19. Thielman, N. M. & Guerrant, R. L. Acute infectious diarrhea. New England Journal of Medicine. 350(1), 38–47 (2004).
20. Spies, L. A. Traveler’s diarrhea: an update on prevention and treatment. J Midwifery Womens Health. 53(3), 251–254 (2008).
21. Vandenplas, Y. Probiotics and prebiotics in infectious gastroenteritis. Best Pract Res Clin Gastroenterol. 30(1), 49–53 (2016).
22. Kim, J. & Shin, W. How to do random allocation (randomization). Clin Orthop Surg. 6(1), 103–110 (2014).
23. Montané, E. et al. Reporting randomised clinical trials of analgesics after traumatic or orthopaedic surgery is inadequate: a systematic review. BMC Clin Pharmacol. 10, 2 (2010).
24. Hrobjartsson, A. What are the main methodological problems in the estimation of placebo effects? J Clin Epidemiol. 55, 430–435 (2002).
25. Datafax Clinical Systems Incorporated. iDatafax Clinical Systems Incorporated, version 4.3.0. Seattle, WA: DF/NET Research INC (2013).
26. McDonald, L. C. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 66, 1–48 (2018).
27. Crobach, M. J. et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 22, 63–81 (2016).
28. Zimmaro Bliss, D., Dhamani, K. A., Savik, K. & Kirk, K. Tool to classify stool consistency: content validity and use by persons of diverse cultures. J Nurs Health Sci. 5(2), 115–121 (2003).
29. Boutron, I. et al. Reporting methods of blinding in randomized trials assessing nonpharmaceutical treatments. PLoS Med. 4(2), 61.
30. Montori, V. et al. In the dark: The reporting of blinding status in randomized controlled trials. J Clin Epidemiol. 55, 787 (2002).
31. Fergusson, D., Glass, K. C., Waring, D. & Shapiro, S. Turning a blind eye: The success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 328, 432 (2004).
32. Faul, F. et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 39, 175–191 (2007).
33. Burgmann, K. & Schoepfer, A. Acute diarrhea. Ther Umsch. 71, 529–535 (2014).
34. Shane, A. L. et al. Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical Infectious Diseases 65, 45–80 (2017).
35. Infectious Diseases Society of America. Handbook on clinical practice guideline development. Available at, http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/IDSA_Practice_Guidelines/IDSA%20Handbook%20on%20CPG%20Development%2015.pdf (2015).
36. Strand, T. A. et al. Risk factors for extended duration of acute diarrhea in young children. PLoS One. 7, 36436 (2012).
37. Malek, M. A. et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics. 117(6), 1887–1892 (2006).
38. Ericsson, C. D. Nonantimicrobial agents in the prevention and treatment of traveler’s diarrhea. Clin Infect Dis. 41, 557–563 (2005).
39. Centers for Disease Control and Prevention (CDC). Foodborne Diseases Active Surveillance Network (FoodNet): FoodNet surveillance report for 2014 (final report). Atlanta, GA: CDC, https://www.cdc.gov/foodnet/pdfs/2014-foodnet-surveillance-report.pdf (2016).
40. MacCannell, T. et al. Healthcare Infection Control Practices Advisory Committee-HICPAC. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infect Control Hosp Epidemiol. 32(10), 939–969 (2011).
41. Gould, D. Management and prevention of norovirus outbreaks in hospitals. Nurs Stand. 23(13), 51–56 (2008).
42. Sadique, Z., Lopman, B., Cooper, B. S. & Edmunds, W. J. Cost-effectiveness of ward closure to control outbreaks of norovirus infection in United Kingdom National Health Service Hospitals. J Infect Dis. 213, 19–26 (2016).
43. Howell, C. A., Mikhalkovsky, S. V., Markaryan, E. N. & Khovanov, A. V. Investigation of the adsorption capacity of the enterosorbent Enterosgel for a range of bacterial toxins, bile acids and pharmaceutical drugs. Sci Rep. 9, 5629 (2019).
44. Howell, C. A. et al. Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial. BMJ Open Gastroenterol. 6, e000287 (2019).
45. Rossignol, J. F., Ayoub, A. & Ayers, M. S. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis. 184(1), 103–106 (2001).
46. Rossignol, J. F., Ayoub, A. & Ayers, M. S. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis. 184(3), 381–384 (2001).
47. Adams, D. A. et al. Nationally Notifiable Infectious Conditions Group. Summary of notifiable infectious diseases and conditions - United States, 2014. MMWR Morb Mortal Wkly Rep. 63(54), 1–152 (2016).
48. Tauxe, R. V. Salmonellosis in nurses: lack of transmission to patients. J Infect Dis. 157(2), 370–373 (1988).
49. Freedman, D. O., Chen, L. H. & Kozarsky, P. E. Medical Considerations before International Travel. N Engl J Med. 375(3), 247–260 (2016).
50. Product Information AEROSIL® 300 Pharma – Colloidal Silicon Dioxide. ECETOC JACC Report No. 51 Synthetic Amorphous Silica (CAS No. 7631-86-9), http://www.ecetoc.org/publication/jacc-report-51-synthetic-amorphous-silica/ (2006).
51. Gray, C. A. & Muranko, H. Studies of robustness of industrial aciniform aggregates and agglomerates—carbon black and amorphous silica: a review amplified by new data. J. Occupational Environ. Med. 48, 1279–1290 (2006).
52. Rimola, A. et al. Silica Surface Features and Their Role in the Adsorption of Biomolecules: Computational Modeling and Experiments. Chem Rev. 12, 4216–4313 (2013).
53. Fruijtier-Pölloth, C. The toxicological mode of action and the safety of synthetic amorphous silica—a nanostructured material. Toxicology. 11, 61–79 (2012).

Acknowledgements
We thank all patients for their participation in the study and we thank:

- Mrs Lyudmila Gordienko, Mr Sergey Kartapov (Kyiv City clinical hospital No. 9);
- Mrs Oleksandra Pryshliak, Mr Oleksander Boychuk (Ivano-Frankivsk regional clinical hospital, Ivano-Frankivsk National Medical University);
- Mrs Larisa Moroz, Mrs Olena Shkondina, Mr Dmytro Paliy (Vinnytsya City clinical hospital No. 1, Vinnytsya National Medical University) and administrative staff, general practices, nurses that assisted with the study. The unique sponsor of the investigation was OMNIFARMA KIEV LLC.

Author contributions
Vadim Tieroshyn initiated the hypothesis and designed the study protocol, contributed to collect, analyze and interpret the data, performed statistical analysis, wrote the manuscript and approved final version of the paper. Larisa Moroz contributed to collect, analyze and interpret the data. Oleksandra Pryshliak and Lyudmila Shostakovich-Koretska contributed to enroll the patients in the study and collected the data. Oksana Kruglova and Lyudmila Gordienko contributed to enroll and randomize the patients; collected and analyzed the data reviewed the source documents. All authors read the manuscript before submitting and agree with final version of the paper.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to V.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020